Caden Biosciences Inc.
www.cadenbiosciences.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Caden Biosciences Inc.
Mind over matter - partnerships: CNS deals signed over the past five years
Attention deficit hyperactivity disorder (ADHD)
Date
Company
Partner
Deal terms
March 2009
GlaxoSmithKline
Shire
co-promotion of Shire's Vyvanse (lisdexamfetamine dimesylate) for the treatment of attention deficit hyperactivity disorder in the US
November 2008
GlaxoSmithKline
Paladin Labs
three-year contract giving Paladin exclusive distribution rights for GSK's Dexedrine (dextroamphetamine sulfate) for the treatment of ADHD and in the adjunctive treatment of narcolepsy, in Canada
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice